<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   &lt;i&gt;Staphylococcus aureus &lt;/i&gt;in children: Overview of treatment of invasive infections
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       <i>
        Staphylococcus aureus
       </i>
       in children: Overview of treatment of invasive infections
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        <i>
         Staphylococcus aureus
        </i>
        in children: Overview of treatment of invasive infections
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheldon L Kaplan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Morven S Edwards, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Diane Blake, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 10, 2024.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          Staphylococcus aureus
         </em>
         is a leading cause of both community-associated and health care-associated invasive infections in children.
        </p>
        <p>
         An overview of the treatment of invasive infections caused by
         <em>
          S. aureus
         </em>
         in infants, children, and adolescents will be provided here. The genetic mechanisms responsible for methicillin resistance; the epidemiology, prevention, and control of methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) infections in children; and the treatment of MRSA skin and soft-tissue infections in infants and children are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3153.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA): Microbiology"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6065.html" rel="external">
          "Methicillin-resistant
          <i>
           Staphylococcus aureus
          </i>
          infections in children: Epidemiology and clinical spectrum"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/106447.html" rel="external">
          "Skin and soft tissue infections in neonates: Evaluation and management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6027.html" rel="external">
          "Skin and soft tissue infections in children &gt;28 days: Evaluation and management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         MRSA, vancomycin-intermediate
         <em>
          S. aureus
         </em>
         (VISA), and vancomycin-resistant
         <em>
          S. aureus
         </em>
         (VRSA) infections in adults also are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">
          "Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3165.html" rel="external">
          "Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3988571347">
         <span class="h1">
          DEFINITIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Invasive infection – Infection of a normally sterile body site; invasive infections commonly associated with
         <em>
          S. aureus
         </em>
         include osteomyelitis, septic arthritis, pneumonia, visceral abscess, endocarditis, bacteremia (whether or not associated with a foreign body), and central nervous system infections (eg, cerebrospinal fluid shunt infection, epidural or subdural empyema, brain abscess)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Methicillin-susceptible
         <em>
          S. aureus
         </em>
         –
         <em>
          S. aureus
         </em>
         isolate with an
         <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">
          oxacillin
         </a>
         minimum inhibitory concentration (MIC) ≤2 mcg/mL
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Methicillin-resistant
         <em>
          S. aureus
         </em>
         –
         <em>
          S. aureus
         </em>
         isolate with an
         <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">
          oxacillin
         </a>
         MIC ≥4 mcg/mL
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          Vancomycin
         </a>
         susceptible
         <em>
          S. aureus
         </em>
         –
         <em>
          S. aureus
         </em>
         isolate with a vancomycin MIC ≤2 mcg/mL
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vancomycin-intermediate
         <em>
          S. aureus
         </em>
         –
         <em>
          S. aureus
         </em>
         isolate with a
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         MIC 4 through 8 mcg/mL
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Vancomycin-resistant
         <em>
          S. aureus
         </em>
         –
         <em>
          S. aureus
         </em>
         isolate with a
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         MIC ≥16 mcg/mL
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1097680779">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specimens for culture and antimicrobial susceptibility testing should be collected whenever possible before initiation of antimicrobial therapy in children with invasive infections suspected to be caused by
         <em>
          S. aureus
         </em>
         given the limited number of antimicrobial agents with activity against methicillin-resistant
         <em>
          S. aureus
         </em>
         and the increasing emergence of multidrug-resistant strains
         <em>
         </em>
         [
         <a href="#rid1">
          1
         </a>
         ]
         <em>
          .
         </em>
         Clinical features are not helpful in predicting methicillin or multidrug resistance.
        </p>
        <p>
         All staphylococci isolated from normally sterile sites should undergo quantitative antimicrobial susceptibility testing (to beta-lactam antibiotics [eg, penicillins, cephalosporins including
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         ],
         <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">
          gentamicin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         , tetracyclines,
         <a class="drug drug_pediatric" data-topicid="13276" href="/z/d/drug information/13276.html" rel="external">
          erythromycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         , and possibly
         <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">
          daptomycin
         </a>
         ) and testing for clindamycin-inducible resistance [
         <a href="#rid2">
          2-5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2705511152">
         <span class="h1">
          INDICATIONS FOR CONSULTATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Consultation with an expert in infectious diseases may be warranted [
         <a href="#rid4">
          4,6
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children with life-threatening infections (eg, sepsis, central nervous system infection, endocarditis, endovascular infection, infection complicated by venous thrombosis, pneumonia complicating influenza)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For guidance regarding choice of antimicrobial therapy (including combination antimicrobial therapy) and duration of therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Before use of
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">
          daptomycin
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12758" href="/z/d/drug information/12758.html" rel="external">
          quinupristin-dalfopristin
         </a>
         (because experience with these agents in children is limited)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children with vancomycin-intermediate
         <em>
          S. aureus
         </em>
         or vancomycin-resistant
         <em>
          S. aureus
         </em>
         infections
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For children who fail to respond to treatment with an agent to which their isolate is susceptible in vitro
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3327465094">
         <span class="h1">
          REMOVAL OF INFECTIOUS FOCI
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of invasive
         <em>
          S. aureus
         </em>
         infection usually requires removal of potential foci of infection (eg, intravascular catheters, purulent collections) [
         <a href="#rid6">
          6-8
         </a>
         ]. Indications for removal of intravascular catheters and surgical drainage of purulent collections are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intravascular catheter removal (see
         <a class="medical medical_review" href="/z/d/html/5967.html" rel="external">
          "Staphylococcus aureus bacteremia in children: Management and outcome", section on 'Intravascular catheter removal'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Parapneumonic effusion, empyema, or lung abscess (see
         <a class="medical medical_review" href="/z/d/html/6345.html" rel="external">
          "Management and prognosis of parapneumonic effusion and empyema in children", section on 'Chest tubes'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6345.html" rel="external">
          "Management and prognosis of parapneumonic effusion and empyema in children", section on 'Surgical therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Osteomyelitis (see
         <a class="medical medical_review" href="/z/d/html/5958.html" rel="external">
          "Hematogenous osteomyelitis in children: Management", section on 'Indications for surgery'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Septic arthritis (see
         <a class="medical medical_review" href="/z/d/html/6033.html" rel="external">
          "Bacterial arthritis: Treatment and outcome in infants and children", section on 'Drainage'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Removal of implants (eg, spinal instrumentation, pacemaker, cochlear implant,
         <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">
          baclofen
         </a>
         pump, prosthetic joint) is often required for successful treatment of implant-associated
         <em>
          S. aureus
         </em>
         infections [
         <a href="#rid9">
          9,10
         </a>
         ]. However, successful treatment with implant retention has been described with a combination of antimicrobial therapy, debridement, and surgical irrigation, particularly if the infection occurs within 90 days of placement [
         <a href="#rid9">
          9,11,12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          EMPIRIC ANTIMICROBIAL THERAPY
         </span>
        </p>
        <p class="headingAnchor" id="H2264414006">
         <span class="h2">
          When to suspect
          <i>
           S. aureus
          </i>
          infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most cases,
         <em>
          S. aureus
         </em>
         infection is suspected because there are clinical findings suggestive of a clinical syndrome or focal source that is associated with
         <em>
          S. aureus
         </em>
         infection. Less commonly,
         <em>
          S. aureus
         </em>
         is suspected because of underlying risk factors or Gram stain demonstrating gram-positive cocci in clusters  (
         <a class="graphic graphic_picture graphicRef72812" href="/z/d/graphic/72812.html" rel="external">
          picture 1
         </a>
         ).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical syndromes associated with
         </strong>
         <strong>
          <em>
           S. aureus
          </em>
         </strong>
         – Clinical syndromes in children that are commonly caused by
         <em>
          S. aureus
         </em>
         are listed below. Empiric therapy for these syndromes is discussed separately. It typically includes coverage for
         <em>
          S. aureus
         </em>
         and also may include coverage for non-staphylococcal pathogens.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Osteomyelitis (see
         <a class="medical medical_review" href="/z/d/html/5958.html" rel="external">
          "Hematogenous osteomyelitis in children: Management", section on 'Empiric parenteral therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Septic arthritis (see
         <a class="medical medical_review" href="/z/d/html/6033.html" rel="external">
          "Bacterial arthritis: Treatment and outcome in infants and children", section on 'Empiric parenteral therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Necrotizing pneumonia, health care-associated pneumonia, pneumonia complicated by empyema, pneumonia complicating influenza or measles, aspiration pneumonia if the child's respiratory tract is colonized with
         <em>
          S. aureus
         </em>
         (see
         <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">
          "Pneumonia in children: Inpatient treatment", section on 'Empiric therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6345.html" rel="external">
          "Management and prognosis of parapneumonic effusion and empyema in children", section on 'Antibiotic therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">
          "Seasonal influenza in children: Management", section on 'Management of coinfection'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Infective endocarditis (see
         <a class="medical medical_review" href="/z/d/html/5768.html" rel="external">
          "Infective endocarditis in children", section on 'Antibiotic regimens'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bacteremia (see
         <a class="medical medical_review" href="/z/d/html/5967.html" rel="external">
          "Staphylococcus aureus bacteremia in children: Management and outcome", section on 'Empiric therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intravascular catheter infection (see
         <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">
          "Intravascular non-hemodialysis catheter-related infection: Treatment"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cerebrospinal fluid shunt infection (see
         <a class="medical medical_review" href="/z/d/html/1286.html" rel="external">
          "Infections of cerebrospinal fluid shunts", section on 'Empiric therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sepsis (see
         <a class="medical medical_review" href="/z/d/html/85767.html" rel="external">
          "Septic shock in children in resource-abundant settings: Rapid recognition and initial resuscitation (first hour)", section on 'Empiric antibiotic therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Toxic shock syndrome (see
         <a class="medical medical_review" href="/z/d/html/3161.html" rel="external">
          "Staphylococcal toxic shock syndrome", section on 'Antibiotic therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intracranial infections, including epidural or subdural abscess
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Risk factors for invasive
         </strong>
         <strong>
          <em>
           S. aureus
          </em>
         </strong>
         <strong>
          infection
         </strong>
         – Although most children with invasive
         <em>
          S. aureus
         </em>
         infections are normal hosts, risk factors for invasive
         <strong>
         </strong>
         <em>
          S. aureus
         </em>
         infection include [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Foreign body (eg, intravascular catheter or graft, peritoneal catheter, cerebrospinal fluid shunt, cardiovascular implantable electronic device, spinal instrumentation or intramedullary rod, cochlear implant,
         <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">
          baclofen
         </a>
         pump, prosthetic joint)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Preceding influenza or measles infection (see
         <a class="medical medical_review" href="/z/d/html/5973.html" rel="external">
          "Seasonal influenza in children: Clinical features and diagnosis", section on 'S. pneumoniae or S. aureus coinfection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3021.html" rel="external">
          "Measles: Clinical manifestations, diagnosis, treatment, and prevention", section on 'Pulmonary'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Malignancy
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prematurity
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immunodeficiency or immunocompromised host (eg, those with phagocyte deficiency or dysfunction, human immunodeficiency virus [HIV] infection)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diabetes mellitus
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3515471300">
         <span class="h2">
          Choice of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We hospitalize children with invasive infections that are suspected to be due to
         <em>
          S. aureus
         </em>
         and provide initial treatment with intravenous (IV) antimicrobial agents [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         The choice of empiric parenteral therapy for suspected invasive
         <em>
          S. aureus
         </em>
         infection in children depends upon the site and severity of the infection, whether infection is health care-associated, the community prevalence of methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) infection, and local susceptibility patterns  (
         <a class="graphic graphic_table graphicRef61437" href="/z/d/graphic/61437.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,4
         </a>
         ]. Information regarding local susceptibility patterns can be obtained from local public health officials or hospital laboratories. Final therapy decisions should be based upon results of cultures and susceptibility testing. (See
         <a class="local">
          'Definitive antimicrobial therapy'
         </a>
         below.)
        </p>
        <p>
         Clinical trials evaluating antimicrobial agents for invasive
         <em>
          S. aureus
         </em>
         infections in children are limited. Our treatment approach is based on case series, in vitro susceptibility testing, and the clinical experience of experts [
         <a href="#rid1">
          1,4
         </a>
         ]. It is generally consistent with the recommendations of the American Academy of Pediatrics [
         <a href="#rid4">
          4
         </a>
         ] and the Infectious Diseases Society of America [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Life-threatening infection (health care- or community-associated)
         </strong>
         – Life-threatening infections include sepsis, central nervous system infections (eg, meningitis, brain abscess, subdural empyema, spinal epidural abscess, septic thrombosis of cavernous or dural venous sinus), endocarditis, endovascular infection, infection complicated by venous thrombosis, and pneumonia complicating influenza. For children with life-threatening infections suspected to be caused by
         <em>
          S. aureus
         </em>
         , we provide initial treatment with
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         <strong>
          plus either
         </strong>
         <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">
          nafcillin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">
          oxacillin
         </a>
         [
         <a href="#rid4">
          4,13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We suggest the following doses:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          Vancomycin
         </a>
         – For children ≤18 years of age, we use an initial dose of 15 mg/kg IV every six hours (maximum daily dose 4 g/day) [
         <a href="#rid14">
          14
         </a>
         ]. Alternative dosing is suggested for clinicians/institutions who use area under the curve (AUC)-guided therapeutic monitoring for vancomycin for serious MRSA infections as suggested by
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.idsociety.org%2Fpractice-guideline%2Fvancomycin%2F&amp;token=1jIv0tCrG79r68%2FYmELnvlmp0mP7K%2FrmIL7haohq7xZjfb4lYZFbZLKqleitPvJZNiWYt56hntBmD%2Bs0VQHiyQ%3D%3D&amp;TOPIC_ID=6057" target="_blank">
          consensus guidelines
         </a>
         [
         <a href="#rid15">
          15
         </a>
         ]; this strategy requires input from a clinical pharmacist, who will provide recommendations for initial dosing  (
         <a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Therapeutic monitoring for vancomycin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">
          Nafcillin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">
          oxacillin
         </a>
         37.5 to 50 mg/kg IV every six hours (maximum daily dose 12 g/day)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional antibiotics may be required for empiric treatment of non-staphylococcal pathogens until the pathogen is identified.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For empiric treatment of suspected MRSA pneumonia complicating influenza, we add a second anti-MRSA (eg,
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         ) to
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         and anti-influenza therapy. Addition of a second anti-MRSA agent within the first 24 hours of admission may be associated with decreased mortality [
         <a href="#rid16">
          16,17
         </a>
         ]. Monotherapy with ceftaroline is an alternative [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">
          "Seasonal influenza in children: Management", section on 'Antiviral therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The combination of
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         plus
         <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">
          nafcillin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">
          oxacillin
         </a>
         is recommended to maximize activity against both MRSA and methicillin-susceptible
         <em>
          S. aureus
         </em>
         . Although other antimicrobial agents have activity against MRSA (eg
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         ) [
         <a href="#rid19">
          19,20
         </a>
         ], we prefer vancomycin given its efficacy and relative safety profile. We also have more clinical experience with vancomycin in treating a variety of invasive clinical syndromes (eg, pneumonia, meningitis).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Alternative regimens for children who cannot tolerate
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         (or are receiving other potentially nephrotoxic drugs) and/or penicillin antibiotics depend upon the clinical scenario:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children
         <strong>
          without
         </strong>
         pneumonia, single drug therapy with
         <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">
          daptomycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         is an alternative.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children
         <strong>
          with
         </strong>
         pneumonia, single-drug therapy with
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         is an alternative.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For children who receive
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         for antistaphylococcal activity and also need activity against gram-negative pathogens, we avoid third- or fourth-generation cephalosporins to prevent confusion in the event of a rash or other adverse reaction. Alternative agents for empiric gram-negative activity include
         <a class="drug drug_pediatric" data-topicid="12949" href="/z/d/drug information/12949.html" rel="external">
          aztreonam
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12549" href="/z/d/drug information/12549.html" rel="external">
          levofloxacin
         </a>
         . Local antibiotic susceptibility reports help guide selection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Consultation with an expert in infectious diseases is recommended because experience with
         <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">
          daptomycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         in children is limited [
         <a href="#rid1">
          1,4,6,18,21-24
         </a>
         ]. Linezolid has the advantage that it is well absorbed orally, so therapy can be completed orally (when clinically appropriate) [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="local">
          'Indications for consultation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonlife-threatening health care-associated infection
         </strong>
         – For children with nonlife-threatening infections (ie, no signs of sepsis) that are suspected to be caused by health care-associated
         <em>
          S. aureus
         </em>
         , we provide initial treatment with
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         15 mg/kg IV every six to eight hours (maximum daily dose 4 g)  (
         <a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid13">
          13
         </a>
         ].
         <em>
          S. aureus
         </em>
         isolates from children with risk factors for health care-associated
         <em>
          S. aureus
         </em>
         are more likely to be resistant to
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         and other drugs than isolates from children without risk factors [
         <a href="#rid25">
          25,26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Risk factors for health care-associated
         <em>
          S. aureus
         </em>
         infection include personal history of or frequent contact with an individual with a history of hospitalization, surgery, dialysis, or residence in a long-term care facility within the previous year, frequent contact with the health care environment, presence of an invasive device (eg, intravascular catheter or tracheal tube), and history of MRSA infection or colonization. (See
         <a class="medical medical_review" href="/z/d/html/6065.html" rel="external">
          "Methicillin-resistant
          <i>
           Staphylococcus aureus
          </i>
          infections in children: Epidemiology and clinical spectrum", section on 'Epidemiology and risk factors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nonlife-threatening community-associated infection
         </strong>
         – For children with nonlife-threatening infections (ie, no signs of sepsis) that are suspected to be caused by community-associated
         <em>
          S. aureus
         </em>
         , empiric antimicrobial therapy depends upon the prevalence of MRSA in the community:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High prevalence of MRSA
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          High prevalence of
         </strong>
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         <strong>
          resistance
         </strong>
         – In communities where MRSA accounts for &gt;10 percent of community
         <em>
          S. aureus
         </em>
         isolates and the prevalence of clindamycin resistance is high (eg, ≥15 percent), we provide initial empiric therapy with
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         15 mg/kg IV every six to eight hours (maximum daily dose 4 g)  (
         <a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid4">
          4,13
         </a>
         ]. For skin and soft tissue infections,
         <a class="drug drug_pediatric" data-topicid="12865" href="/z/d/drug information/12865.html" rel="external">
          trimethoprim
         </a>
         (TMP)-sulfamethoxazole (20 mg TMP/kg/day in divided doses every six hours intravenously) is another option.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Low prevalence of
         </strong>
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         <strong>
          resistance
         </strong>
         – In communities where MRSA accounts for &gt;10 percent of community
         <em>
          S. aureus
         </em>
         isolates, the prevalence of clindamycin resistance is low (eg, &lt;15 percent), and intravenous clindamycin is readily available, we provide initial empiric therapy with clindamycin 40 mg/kg per day IV divided in three or four doses (maximum daily dose 2.7 g/day) if bacteremia is not likely [
         <a href="#rid2">
          2,4,13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          Clindamycin
         </a>
         should
         <strong>
          not
         </strong>
         be used for empiric treatment of invasive infections in communities with high rates of clindamycin resistance (constitutive plus inducible), as treatment failures have occurred [
         <a href="#rid27">
          27-29
         </a>
         ]. The threshold prevalence of clindamycin-resistant MRSA (constitutive plus inducible) for choosing
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         varies from center to center, usually ranging from 10 to 25 percent, in an effort to balance the benefit of definitive therapy for the patient with the risk of increasing vancomycin resistance in the community. Additional considerations in the decision to choose vancomycin include the prevalence of MRSA in the community, the severity of illness, renal function and/or use of other nephrotoxic agents, and the turn-around time for susceptibilities.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Most community-associated MRSA (CA-MRSA) strains are susceptible to non-beta-lactam antibiotics (eg,
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         ) [
         <a href="#rid30">
          30-33
         </a>
         ]. However, there is variability among CA-MRSA strains. Some are resistant to multiple drugs and some have susceptibility patterns similar to health care-associated MRSA isolates [
         <a href="#rid27">
          27,28,34-36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low prevalence of MRSA
         </strong>
         – In communities where MRSA accounts for &lt;10 percent of community
         <em>
          S. aureus
         </em>
         isolates,
         <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">
          nafcillin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">
          oxacillin
         </a>
         150 to 200 mg/kg per day IV in four doses (maximum daily dose 12 g/day) may be used for empiric therapy [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          DEFINITIVE ANTIMICROBIAL THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Definitive antimicrobial therapy is determined by culture and susceptibility results.
        </p>
        <p class="headingAnchor" id="H2427150429">
         <span class="h2">
          MSSA infection
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Central nervous system infection
         </strong>
         – Treatment of methicillin-susceptible
         <em>
          S. aureus
         </em>
         (MSSA) central nervous system (CNS) infections is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6010.html" rel="external">
          "Bacterial meningitis in children older than one month: Treatment and prognosis", section on 'Specific therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection outside the CNS
         </strong>
         – For the treatment of MSSA infections outside the CNS, we prefer one of the following regimens  (
         <a class="graphic graphic_table graphicRef57379" href="/z/d/graphic/57379.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid4">
          4,13,37
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">
          Nafcillin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">
          oxacillin
         </a>
         150 to 200 mg/kg per day IV in four doses (maximum daily dose 12 g/day)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13124" href="/z/d/drug information/13124.html" rel="external">
          Cefazolin
         </a>
         100 mg/kg per day IV in three doses (maximum daily dose 6 g/day); for bone and joint infections, the dose may be increased up to 150 mg/kg per day IV in three or four doses (safety data are limited) [
         <a href="#rid38">
          38
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">
          Nafcillin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">
          oxacillin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13124" href="/z/d/drug information/13124.html" rel="external">
          cefazolin
         </a>
         are more effective than
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         for the treatment of MSSA [
         <a href="#rid39">
          39-41
         </a>
         ]. Some MSSA isolates demonstrate higher minimum inhibitory concentrations (MICs) to cefazolin when tested at a higher inoculum (10
         <sup>
          7
         </sup>
         cfu/mL) compared with the standard inoculum density (10
         <sup>
          5
         </sup>
         cfu/mL), the so-called "cefazolin inoculum effect" (CIE). The clinical implications for using cefazolin to treat children with an invasive MSSA infection due to an isolate demonstrating this effect is unclear [
         <a href="#rid42">
          42
         </a>
         ]. CIE is only determined in research laboratories.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to antistaphylococcal therapy, adjunctive antimicrobial therapy may be warranted for children with prosthetic valve endocarditis or other device-related infection (eg, spinal instrumentation, cardiovascular implantable electronic device (CIED), cochlear implant,
         <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">
          baclofen
         </a>
         pump, prosthetic joint). (See
         <a class="local">
          'Adjunctive therapy for device-related infections'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For children with MSSA infections outside the CNS who are unable to tolerate penicillin and cephalosporin antibiotics, we use [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          Clindamycin
         </a>
         40 mg/kg per day IV in three or four doses (maximum daily dose 2.7 g/day) if the isolate is clindamycin susceptible and the child does not have endocarditis or ongoing bacteremia,
         <strong>
          or
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          Vancomycin
         </a>
         60 mg/kg per day IV in four doses (maximum daily dose 4 g/day)  (
         <a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Polymicrobial infection
         </strong>
         – For children with polymicrobial infections that include MSSA,
         <a class="drug drug_pediatric" data-topicid="12695" href="/z/d/drug information/12695.html" rel="external">
          ampicillin-sulbactam
         </a>
         can be used alone if the non-
         <em>
          S. aureus
         </em>
         isolates are susceptible. Alternative agents for monotherapy for susceptible isolates include
         <a class="drug drug_pediatric" data-topicid="13124" href="/z/d/drug information/13124.html" rel="external">
          cefazolin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12708" href="/z/d/drug information/12708.html" rel="external">
          piperacillin-tazobactam
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13136" href="/z/d/drug information/13136.html" rel="external">
          ceftriaxone
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13126" href="/z/d/drug information/13126.html" rel="external">
          cefepime
         </a>
         [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h2">
          MRSA infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         Methicillin resistance in
         <em>
          S. aureus
         </em>
         is defined as an
         <a class="drug drug_pediatric" data-topicid="12663" href="/z/d/drug information/12663.html" rel="external">
          oxacillin
         </a>
         MIC ≥4 mcg/mL. Isolates resistant to oxacillin or methicillin are resistant to other beta-lactam agents, including cephalosporins (with the exception of
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         and
         <a class="drug drug_general" data-topicid="9001" href="/z/d/drug information/9001.html" rel="external">
          ceftobiprole
         </a>
         ). Definitive therapy for invasive methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) infections depends upon the type of infection, susceptibility of the isolate, and results of testing for inducible resistance to
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         (
         <a class="graphic graphic_table graphicRef78349" href="/z/d/graphic/78349.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid1">
          1,4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1893072472">
         <span class="h3">
          Health care-associated MRSA
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with invasive health care-associated MRSA infections, we prefer
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         15 mg/kg IV every six hours (maximum daily dose 4 g/day)  (
         <a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">
          table 2
         </a>
         ) to other antistaphylococcal agents  (
         <a class="graphic graphic_table graphicRef78349" href="/z/d/graphic/78349.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid4">
          4,13
         </a>
         ]. We prefer vancomycin because of its efficacy and relative safety, and because we have more clinical experience with vancomycin in treating a variety of invasive MRSA infections.
        </p>
        <p>
         In addition to antistaphylococcal therapy, adjunctive antimicrobial therapy may be warranted for children with prosthetic valve endocarditis or other device-related infection (eg, spinal instrumentation, pacemaker, cochlear implant,
         <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">
          baclofen
         </a>
         pump, prosthetic joint). (See
         <a class="local">
          'Adjunctive therapy for device-related infections'
         </a>
         below.)
        </p>
        <p>
         For children who cannot tolerate
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         or for whom nephrotoxicity is a concern, consultation with an expert in infectious diseases is recommended. The preferred agent varies with susceptibility and clinical features including the site of infection. Possibilities include
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">
          daptomycin
         </a>
         (except in children with pneumonia),
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12816" href="/z/d/drug information/12816.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         (TMP-SMX)  (
         <a class="graphic graphic_table graphicRef78349" href="/z/d/graphic/78349.html" rel="external">
          table 4
         </a>
         ). Alternatives to vancomycin for CNS infections include linezolid, daptomycin, and TMP-SMX [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
         TMP-SMX and
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         have the advantage of oral formulations, so that therapy can be completed orally (when clinically appropriate) [
         <a href="#rid2">
          2
         </a>
         ]. Consultation with an expert in infectious diseases is suggested before use of linezolid,
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">
          daptomycin
         </a>
         because clinical experience with these agents in children is limited [
         <a href="#rid4">
          4,45,46
         </a>
         ]. (See
         <a class="local">
          'Indications for consultation'
         </a>
         above.)
        </p>
        <p>
         Although limited, some data suggest a role for
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         in the treatment of staphylococcal infections in children [
         <a href="#rid47">
          47-49
         </a>
         ]. In subgroup analysis of a randomized trial, among children hospitalized with MRSA pneumonia, bacteremia, or complicated skin infection, clinical and microbiologic cure rates were approximately 90 percent for both linezolid and
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         [
         <a href="#rid49">
          49
         </a>
         ].Published experience with
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">
          daptomycin
         </a>
         in children with invasive MRSA infections is also limited, but growing [
         <a href="#rid50">
          50-52
         </a>
         ].
        </p>
        <p>
         There are no randomized trials evaluating TMP-SMX for the treatment of invasive MRSA infections in children. However, two retrospective studies suggest TMP-SMX may be an oral option to complete MRSA osteomyelitis therapy [
         <a href="#rid53">
          53,54
         </a>
         ]. In randomized trials in adults, TMP-SMX has been less effective than
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         for the treatment of serious MRSA infections [
         <a href="#rid55">
          55,56
         </a>
         ]. However, in one trial, bacteriologic cure was achieved in 86 percent of patients with serious MRSA infection (compared with 98 percent for vancomycin) [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1755313162">
         <span class="h3">
          Community-associated MRSA
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Life-threatening infection
         </strong>
         – Life-threatening infections include sepsis, central nervous system infections, endocarditis, endovascular infection, infection complicated by venous thrombosis, and pneumonia complicating influenza.
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          Vancomycin
         </a>
         15 mg/kg IV every six hours (maximum daily dose 4 g)  (
         <a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">
          table 2
         </a>
         ) is preferred for the treatment of life-threatening community-associated MRSA (CA-MRSA) infections [
         <a href="#rid4">
          4,13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For pneumonia complicating influenza, we add a second anti-MRSA (eg,
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         ) to
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         and anti-influenza therapy. Addition of a second anti-MRSA agent within the first 24 hours of admission may be associated with decreased mortality [
         <a href="#rid16">
          16,17
         </a>
         ]. Ceftaroline monotherapy is another option for pneumonia complicating influenza [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5985.html" rel="external">
          "Seasonal influenza in children: Management", section on 'Antiviral therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to antistaphylococcal therapy, adjunctive antimicrobial therapy may be warranted for children with prosthetic valve endocarditis or other device-related infection (eg, spinal instrumentation, pacemaker, cochlear implant,
         <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">
          baclofen
         </a>
         pump, prosthetic joint). (See
         <a class="local">
          'Adjunctive therapy for device-related infections'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Consultation with an expert in infectious diseases is recommended if
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         cannot be administered (eg, for children with renal dysfunction). Alternatives to vancomycin include
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">
          daptomycin
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         . Ceftaroline or daptomycin are preferred to linezolid because cases of apparent failure of linezolid to treat or prevent endocarditis in patients with intravascular MRSA infection have been described [
         <a href="#rid57">
          57-59
         </a>
         ]. Linezolid is well absorbed orally, so therapy can be completed orally (when clinically appropriate) [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pneumonia, septic arthritis, or osteomyelitis
         </strong>
         – For the treatment of CA-MRSA septic arthritis, osteomyelitis, or pneumonia without concomitant influenza, we prefer
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         40 mg/kg per day in three or four doses (maximum daily dose 2.7 g/day) if the isolate is susceptible [
         <a href="#rid4">
          4,13
         </a>
         ]. Clindamycin is well absorbed orally, so therapy can be completed orally (when clinically appropriate) [
         <a href="#rid2">
          2
         </a>
         ]. In retrospective observational studies, clindamycin has been effective in the treatment of CA-MRSA infections in children [
         <a href="#rid60">
          60,61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children with pneumonia,
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         is an option if the isolate is resistant to
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         (
         <a class="graphic graphic_table graphicRef78349" href="/z/d/graphic/78349.html" rel="external">
          table 4
         </a>
         ).
         <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">
          Daptomycin
         </a>
         should
         <strong>
          not
         </strong>
         be used for treatment of pneumonia because its activity is inhibited by pulmonary surfactant [
         <a href="#rid62">
          62,63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For children with septic arthritis or osteomyelitis,
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">
          daptomycin
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         are options if the isolate is resistant to
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         (
         <a class="graphic graphic_table graphicRef78349" href="/z/d/graphic/78349.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6033.html" rel="external">
          "Bacterial arthritis: Treatment and outcome in infants and children", section on 'Pathogen-directed therapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5958.html" rel="external">
          "Hematogenous osteomyelitis in children: Management", section on 'Pathogen-directed therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Consultation with an expert in infectious diseases is suggested before use of
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">
          daptomycin
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         because clinical experience with these agents in children is lacking.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Experience with
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         for the treatment of serious staphylococcal infections in children is limited, but growing [
         <a href="#rid20">
          20,47-49
         </a>
         ]. In a randomized trial in 321 hospitalized children (0 to 11 years) with gram-positive pneumonia, bacteremia, or complicated skin infections, overall clinical cure rates were similar among children treated with linezolid and
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         (79 and 74 percent, respectively) [
         <a href="#rid20">
          20
         </a>
         ]. Among children with MRSA, clinical cure rates were 94 and 90 percent, and bacteriologic cure rates were 88 and 90 percent, respectively [
         <a href="#rid49">
          49
         </a>
         ]. Similar findings have been reported in adults [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">
          Daptomycin
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         have activity against MRSA, as well as against other resistant gram-positive bacteria [
         <a href="#rid62">
          62,64,65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serious skin and soft tissue infections
         </strong>
         – The management of serious MRSA skin and soft tissue infections (SSTIs) in children, including MRSA SSTIs that require hospitalization, is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/106447.html" rel="external">
          "Skin and soft tissue infections in neonates: Evaluation and management", section on 'SSTI more severe than localized pustulosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6027.html" rel="external">
          "Skin and soft tissue infections in children &gt;28 days: Evaluation and management", section on 'Systemic antimicrobial therapy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2746440715">
         <span class="h2">
          Adjunctive therapy for device-related infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         For children with prosthetic valve endocarditis or other device-related infections, we add
         <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">
          gentamicin
         </a>
         and/or
         <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">
          rifampin
         </a>
         to antistaphylococcal therapy as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prosthetic valve endocarditis
         </strong>
         – For
         <em>
          S. aureus
         </em>
         prosthetic valve endocarditis, we
         <strong>
          add
         </strong>
         <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">
          gentamicin
         </a>
         1 mg/kg three times per day IV and
         <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">
          rifampin
         </a>
         10 mg/kg orally or IV twice per day (maximum daily dose 600 mg) for the first two weeks of treatment [
         <a href="#rid1">
          1,66
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2141.html" rel="external">
          "Antimicrobial therapy of prosthetic valve endocarditis", section on 'Staphylococci'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other device-related infections
         </strong>
         – For children with other device-related
         <em>
          S. aureus
         </em>
         infections (eg, spinal instrumentation, CIED, cochlear implant,
         <a class="drug drug_pediatric" data-topicid="12983" href="/z/d/drug information/12983.html" rel="external">
          baclofen
         </a>
         pump, prosthetic joint), we
         <strong>
          add
         </strong>
         <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">
          rifampin
         </a>
         10 mg/kg orally or IV twice per day (maximum daily dose 600 mg) for up to two months if rifampin is tolerated and the device remains in place.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h2">
          VISA infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vancomycin-intermediate
         <em>
          S. aureus
         </em>
         (VISA) is defined as a
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         MIC 4 to 8 mcg/mL [
         <a href="#rid67">
          67,68
         </a>
         ]. VISA isolates have been rarely reported in children [
         <a href="#rid69">
          69
         </a>
         ]. Consultation with an expert in infectious diseases is suggested in the management of children with VISA infections [
         <a href="#rid4">
          4
         </a>
         ]. Optimal therapy for VISA infections in children has yet to be determined.
        </p>
        <p>
         The choice of antibiotic depends upon the results of in vitro susceptibility studies. For children with a susceptible isolate, we prefer
         <strong>
          one
         </strong>
         of the following regimens if the isolate is susceptible [
         <a href="#rid4">
          4,13,70
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          Linezolid
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         &lt;12 years: 30 mg/kg intravenously (IV) per day in three doses
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         ≥12 years: 600 mg IV twice per day
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          Ceftaroline
         </a>
         15 mg/kg per dose IV (administered over 2 hours) every eight hours; maximum dose 600 mg
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">
          Daptomycin
         </a>
         (except for children with pneumonia)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         1 through 6 years: 12 mg/kg IV once daily
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         7 through 11 years: 9 mg/kg IV once daily
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         12 through 17 years: 7 mg/kg IV once daily
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12758" href="/z/d/drug information/12758.html" rel="external">
          Quinupristin-dalfopristin
         </a>
         7.5 mg/kg per dose IV three times per day (requires central venous access)
        </p>
        <p>
        </p>
        <p>
         Alternative regimens include
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         combined with
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         (with or without
         <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">
          gentamicin
         </a>
         ) or vancomycin combined with TMP-SMX [
         <a href="#rid4">
          4
         </a>
         ]. We add gentamicin and
         <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">
          rifampin
         </a>
         for the first two weeks of treatment of prosthetic valve endocarditis. We add rifampin for the treatment of other device-related infections (eg, spinal instrumentation, prosthetic joint).
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h2">
          VRSA infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vancomycin-resistant
         <em>
          S. aureus
         </em>
         (VRSA) is defined as a
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         MIC ≥16 mcg/mL [
         <a href="#rid67">
          67,68
         </a>
         ]. VRSA isolates have been rarely reported in children [
         <a href="#rid69">
          69
         </a>
         ]. VRSA strains have been susceptible to several other agents, including
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12758" href="/z/d/drug information/12758.html" rel="external">
          quinupristin-dalfopristin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13009" href="/z/d/drug information/13009.html" rel="external">
          daptomycin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="109476" href="/z/d/drug information/109476.html" rel="external">
          ceftaroline
         </a>
         [
         <a href="#rid71">
          71-75
         </a>
         ]. Consultation with an expert in pediatric infectious diseases is suggested in the management of children with VRSA infections. (See
         <a class="medical medical_review" href="/z/d/html/3165.html" rel="external">
          "Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H701363166">
         <span class="h1">
          THERAPEUTIC MONITORING FOR VANCOMYCIN
         </span>
        </p>
        <p class="headingAnchor" id="H3031203395">
         <span class="h2">
          Indications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The indications for therapeutic monitoring for
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         may vary from institution to institution. We routinely perform therapeutic monitoring for vancomycin in children with renal dysfunction, infective endocarditis, and children with risk factors for altered vancomycin kinetics (eg, fluid overload, critical illness).
        </p>
        <p>
         For children with other serious staphylococcal infections (eg, pneumonia requiring hospitalization, osteomyelitis, central nervous system infection), we make decisions about therapeutic monitoring on a case-by-case basis, considering the anticipated duration of
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         therapy and other clinical factors (eg, additional nephrotoxic drugs).
        </p>
        <p class="headingAnchor" id="H524836593">
         <span class="h2">
          Choice of strategy
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are two methods of therapeutic monitoring for
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         : trough-guided dosing and area under the curve (AUC)-guided dosing, which requires the assistance of a clinical pharmacist  (
         <a class="graphic graphic_table graphicRef129344" href="/z/d/graphic/129344.html" rel="external">
          table 2
         </a>
         ). The preferred approach may vary from facility to facility.
        </p>
        <p>
         We generally favor trough-guided monitoring. Although AUC-guided dosing is suggested by consensus guidelines [
         <a href="#rid15">
          15
         </a>
         ], the advantages and feasibility of this approach for most pediatric facilities remain to be determined [
         <a href="#rid14">
          14,76
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Trough-guided dosing
         </strong>
         – When indicated, we usually obtain
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         trough concentrations immediately before the third or fourth dose of vancomycin. We aim to achieve trough concentrations of 5 to 15 mcg/mL and extend the dosing interval if the trough is ≥15 mcg/mL [
         <a href="#rid15">
          15
         </a>
         ]. In one report, vancomycin trough levels &lt;10 mcg/mL within the first 72 hours of treatment were associated with a longer duration of MRSA bacteremia [
         <a href="#rid52">
          52
         </a>
         ]. Although trough concentrations ≥15 mcg/mL have been recommended for adult patients [
         <a href="#rid1">
          1,77
         </a>
         ], in observational studies in children, trough concentrations ≥15 mcg/mL have not been associated with improved outcomes and have been associated with increased risk of acute kidney injury [
         <a href="#rid78">
          78-81
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Once the target trough has been achieved, we continue to monitor trough concentrations in children with abnormal renal function after one or several subsequent doses to monitor the dosing interval; we consult a clinical pharmacist as necessary for guidance. For children whose renal function has returned to normal and whose
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         course will be prolonged (eg, &gt;2 weeks), we monitor trough concentrations every 7 to 10 days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          AUC-guided dosing
         </strong>
         – In the AUC-guided approach, the
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         dose is adjusted based on the ratio of the AUC over 24 hours to the minimum inhibitory concentration (AUC/MIC) [
         <a href="#rid15">
          15
         </a>
         ]. Clinical pharmacists can use software programs to estimate the AUC/MIC from serum peak and trough vancomycin levels ideally obtained within 24 to 48 hours of initiation of treatment. The target AUC/MIC is 400, assuming a vancomycin MIC of 1 mg/L.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional details of AUC-guided dosing for children are provided in the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.idsociety.org%2Fpractice-guideline%2Fvancomycin%2F&amp;token=1jIv0tCrG79r68%2FYmELnvlmp0mP7K%2FrmIL7haohq7xZjfb4lYZFbZLKqleitPvJZNiWYt56hntBmD%2Bs0VQHiyQ%3D%3D&amp;TOPIC_ID=6057" target="_blank">
          consensus guideline
         </a>
         [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="local">
          'Society guideline links'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h1">
          DURATION OF THERAPY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The duration of therapy for invasive
         <em>
          S. aureus
         </em>
         infection depends upon the site but usually is at least four weeks for endocarditis, osteomyelitis, necrotizing pneumonia, and disseminated infection, provided that the child responds clinically and microbiologically [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p>
         Parenteral therapy is recommended for the entire course in patients with endocarditis and central nervous system infections. Oral therapy may be used for a portion of the course in patients with other types of infection.
        </p>
        <p>
         Duration of therapy and criteria for switching to oral therapy for specific clinical syndromes are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infective endocarditis (see
         <a class="medical medical_review" href="/z/d/html/5768.html" rel="external">
          "Infective endocarditis in children", section on 'Antibiotic regimens'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Osteomyelitis (see
         <a class="medical medical_review" href="/z/d/html/5958.html" rel="external">
          "Hematogenous osteomyelitis in children: Management", section on 'Total duration'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Septic arthritis (see
         <a class="medical medical_review" href="/z/d/html/6033.html" rel="external">
          "Bacterial arthritis: Treatment and outcome in infants and children", section on 'Total duration'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pneumonia/empyema (see
         <a class="medical medical_review" href="/z/d/html/6054.html" rel="external">
          "Pneumonia in children: Inpatient treatment", section on 'Duration of treatment'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6345.html" rel="external">
          "Management and prognosis of parapneumonic effusion and empyema in children", section on 'Duration'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bacterial meningitis (see
         <a class="medical medical_review" href="/z/d/html/6010.html" rel="external">
          "Bacterial meningitis in children older than one month: Treatment and prognosis", section on 'Treatment duration'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sepsis (see
         <a class="medical medical_review" href="/z/d/html/86881.html" rel="external">
          "Septic shock in children in resource-abundant settings: Ongoing management after resuscitation", section on 'Eradicate infection'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Toxic shock syndrome (see
         <a class="medical medical_review" href="/z/d/html/3161.html" rel="external">
          "Staphylococcal toxic shock syndrome", section on 'Duration of therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bacteremia (see
         <a class="medical medical_review" href="/z/d/html/5967.html" rel="external">
          "Staphylococcus aureus bacteremia in children: Management and outcome", section on 'Duration of therapy'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intravascular catheter infection (see
         <a class="medical medical_review" href="/z/d/html/3814.html" rel="external">
          "Intravascular non-hemodialysis catheter-related infection: Treatment"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          TREATMENT OF NEONATES
         </span>
         <span class="headingEndMark">
          —
         </span>
         We hospitalize infants ≤28 days who have been evaluated for invasive infection and provide the entire course of antimicrobial therapy parenterally [
         <a href="#rid82">
          82
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6072.html" rel="external">
          "The febrile infant (29 to 90 days of age): Outpatient evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106744.html" rel="external">
          "The febrile infant (29 to 90 days of age): Management"
         </a>
         .)
        </p>
        <p>
         Empiric antimicrobial therapy for
         <em>
          S. aureus
         </em>
         infection in neonates should be based upon the local susceptibility pattern of community-associated
         <em>
          S. aureus
         </em>
         isolates. Information regarding local susceptibility patterns can be obtained from local public health officials or hospital laboratories. The author's institution uses
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">
          nafcillin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">
          gentamicin
         </a>
         for neonates with suspected invasive staphylococcal infection  (
         <a class="graphic graphic_table graphicRef64140" href="/z/d/graphic/64140.html" rel="external">
          table 5
         </a>
         ). Gentamicin is included to cover possible gram-negative enteric pathogens.
        </p>
        <p>
         If methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) infection is confirmed, intravenous
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         is preferred [
         <a href="#rid1">
          1
         </a>
         ];
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         are alternatives for nonendovascular MRSA infections [
         <a href="#rid4">
          4
         </a>
         ]. Linezolid should be used in consultation with an expert in infectious diseases. The doses of the suggested antimicrobial agents are provided in the table  (
         <a class="graphic graphic_table graphicRef64140" href="/z/d/graphic/64140.html" rel="external">
          table 5
         </a>
         ). Our recommendations are generally consistent with the Infectious Diseases Society of America guidance for the management of invasive MRSA infections in infants (≤28 days of age) [
         <a href="#rid1">
          1
         </a>
         ], which are based upon observations from a single-institution review of 126 cases treated between 2001 and 2006 [
         <a href="#rid82">
          82
         </a>
         ].
        </p>
        <p>
         In a randomized trial in 63 neonates hospitalized with known or suspected resistant gram-positive infections, clinical and microbiologic cure rates were similar with
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         [
         <a href="#rid48">
          48
         </a>
         ];
         <em>
          S. aureus
         </em>
         accounted for 12 of 50 infections with a known pathogen.
        </p>
        <p>
         General aspects of management of invasive infections in neonates are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6016.html" rel="external">
          "Bacterial meningitis in the neonate: Treatment and outcome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4959.html" rel="external">
          "Urinary tract infections in neonates"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5004.html" rel="external">
          "Neonatal pneumonia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/106447.html" rel="external">
          "Skin and soft tissue infections in neonates: Evaluation and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          TREATMENT FAILURE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients with invasive
         <em>
          S. aureus
         </em>
         infections fail to respond to treatment with an agent to which their isolate is susceptible in vitro [
         <a href="#rid6">
          6
         </a>
         ]. Potential reasons for this include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poor source control (eg, loculated parapneumonic effusion, incomplete drainage of abscesses, infected device remains in place)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reduced antimicrobial concentration at the site of infection [
         <a href="#rid83">
          83-85
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Heteroresistance to
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         (eg, subpopulations of organisms with reduced susceptibility) (see
         <a class="medical medical_review" href="/z/d/html/467.html" rel="external">
          "Overview of antibacterial susceptibility testing", section on 'Heteroresistance'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Strategies to overcome these problems include the addition of adjunctive antimicrobial agents (eg,
         <a class="drug drug_pediatric" data-topicid="12767" href="/z/d/drug information/12767.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">
          gentamicin
         </a>
         ) and/or a change in antimicrobial therapy [
         <a href="#rid1">
          1,86
         </a>
         ]. In either case, consultation with an expert in pediatric infectious diseases is recommended.
        </p>
        <p class="headingAnchor" id="H4093177008">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110550.html" rel="external">
          "Society guideline links: Management of
          <i>
           Staphylococcus aureus
          </i>
          infection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword[s] of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/4025.html" rel="external">
          "Patient education: Methicillin-resistant Staphylococcus aureus (MRSA) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Specimens for culture and antimicrobial susceptibility testing should be collected whenever possible before initiation of antimicrobial therapy in children with invasive infections suspected to be caused by
         <em>
          Staphylococcus aureus.
         </em>
         All staphylococci isolated from normally sterile sites should undergo quantitative antimicrobial susceptibility and testing for clindamycin-inducible resistance. (See
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Management of invasive
         <em>
          S. aureus
         </em>
         infection usually requires removal of potential foci of infection (eg, intravascular catheters, purulent collections). (See
         <a class="local">
          'Removal of infectious foci'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In most cases, invasive
         <em>
          S. aureus
         </em>
         infection is suspected because there are clinical findings suggestive of a clinical syndrome or focal source that is associated with
         <em>
          S. aureus
         </em>
         infection (eg, osteomyelitis, septic arthritis, pneumonia, infective endocarditis, foreign body-associated bacteremia). Less commonly,
         <em>
          S. aureus
         </em>
         is suspected because of underlying risk factors (eg, diabetes mellitus, immunodeficiency) or Gram stain demonstrating gram-positive cocci in clusters. (See
         <a class="local">
          'When to suspect S. aureus infection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We hospitalize children with invasive infections that are suspected to be due to
         <em>
          S. aureus
         </em>
         and provide initial treatment with intravenous antimicrobial agents. The choice of empiric therapy for suspected invasive
         <em>
          S. aureus
         </em>
         infection in children depends upon the site and severity of the infection, the community prevalence of methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) infection, and local susceptibility patterns  (
         <a class="graphic graphic_table graphicRef61437" href="/z/d/graphic/61437.html" rel="external">
          table 1
         </a>
         ). Additional antibiotics may be required for non-staphylococcal pathogens until the pathogen is identified. (See
         <a class="local">
          'Empiric antimicrobial therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Definitive antimicrobial therapy for
         <em>
          S. aureus
         </em>
         infections is determined by culture and whether the isolate is methicillin-susceptible  (
         <a class="graphic graphic_table graphicRef57379" href="/z/d/graphic/57379.html" rel="external">
          table 3
         </a>
         ) or methicillin-resistant  (
         <a class="graphic graphic_table graphicRef78349" href="/z/d/graphic/78349.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Definitive antimicrobial therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The duration of therapy for invasive
         <em>
          S. aureus
         </em>
         infection depends upon the site of infection and clinical response to treatment. It is usually at least four weeks for endocarditis, osteomyelitis, necrotizing pneumonia, and disseminated infection, provided that the child responds clinically and microbiologically. Parenteral therapy is recommended for the entire course for children with endocarditis and central nervous system infections. Oral therapy may be used for a portion of the course in patients with other types of infection. (See
         <a class="local">
          'Duration of therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We hospitalize infants ≤28 days who have been evaluated for invasive infection and provide the entire course of antimicrobial therapy parenterally. The author's institution uses
         <a class="drug drug_pediatric" data-topicid="12874" href="/z/d/drug information/12874.html" rel="external">
          vancomycin
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12626" href="/z/d/drug information/12626.html" rel="external">
          nafcillin
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="13332" href="/z/d/drug information/13332.html" rel="external">
          gentamicin
         </a>
         for neonates with suspected invasive staphylococcal infection  (
         <a class="graphic graphic_table graphicRef64140" href="/z/d/graphic/64140.html" rel="external">
          table 5
         </a>
         ). If MRSA infection is confirmed, intravenous vancomycin is preferred;
         <a class="drug drug_pediatric" data-topicid="13167" href="/z/d/drug information/13167.html" rel="external">
          clindamycin
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="12555" href="/z/d/drug information/12555.html" rel="external">
          linezolid
         </a>
         are alternatives for nonendovascular MRSA infections. (See
         <a class="local">
          'Treatment of neonates'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan SL. Treatment of community-associated methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J 2005; 24:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jimenez-Truque N, Thomsen I, Saye E, Creech CB. Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children? Pediatr Infect Dis J 2010; 29:368.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Staphylococcus aureus. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, Itasca, IL 2021. p.678.
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeil JC, Sommer LM, Vallejo JG, et al. Reduced Ceftaroline Susceptibility among Invasive MRSA Infections in Children: a Clinical and Genomic Investigation. Antimicrob Agents Chemother 2022; 66:e0074522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fergie J, Purcell K. The treatment of community-acquired methicillin-resistant Staphylococcus aureus infections. Pediatr Infect Dis J 2008; 27:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pannaraj PS, Hulten KG, Gonzalez BE, et al. Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 2006; 43:953.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foster CE, Lamberth LB, Kaplan SL, Hulten KG. Clinical Characteristics and Outcomes of Staphylococcus aureus Implant-associated Infections in Children. Pediatr Infect Dis J 2019; 38:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cahill PJ, Warnick DE, Lee MJ, et al. Infection after spinal fusion for pediatric spinal deformity: thirty years of experience at a single institution. Spine (Phila Pa 1976) 2010; 35:1211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamberet A, Violas P, Buffet-Bataillon S, et al. Postoperative Spinal Implant Infections in Children: Risk Factors, Characteristics and Outcome. Pediatr Infect Dis J 2018; 37:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glotzbecker MP, Gomez JA, Miller PE, et al. Management of Spinal Implants in Acute Pediatric Surgical Site Infections: A Multicenter Study. Spine Deform 2016; 4:277.
          </a>
         </li>
         <li class="breakAll">
          American Academy of Pediatrics. Tables of antibacterial drug dosages. In: Red Book: 2021-2024 Report of the Committee on Infectious Diseases, 32nd ed, Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH (Eds), American Academy of Pediatrics, 2021. p.876.
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeil JC, Kaplan SL. Vancomycin Therapeutic Drug Monitoring in Children: New Recommendations, Similar Challenges. J Pediatr Pharmacol Ther 2020; 25:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Randolph AG, Xu R, Novak T, et al. Vancomycin Monotherapy May Be Insufficient to Treat Methicillin-resistant Staphylococcus aureus Coinfection in Children With Influenza-related Critical Illness. Clin Infect Dis 2019; 68:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thomsen IP. The Concern for Vancomycin Failure in the Treatment of Pediatric Staphylococcus aureus Disease. Clin Infect Dis 2019; 68:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blumer JL, Ghonghadze T, Cannavino C, et al. A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia. Pediatr Infect Dis J 2016; 35:760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens DL, Herr D, Lampiris H, et al. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002; 34:1481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan SL, Deville JG, Yogev R, et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr Infect Dis J 2003; 22:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan SL. Implications of methicillin-resistant Staphylococcus aureus as a community-acquired pathogen in pediatric patients. Infect Dis Clin North Am 2005; 19:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Mendes RE, Castanheira M, et al. Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014. Pediatr Infect Dis J 2017; 36:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Korczowski B, Antadze T, Giorgobiani M, et al. A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection. Pediatr Infect Dis J 2016; 35:e239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cannavino CR, Nemeth A, Korczowski B, et al. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone. Pediatr Infect Dis J 2016; 35:752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaoutis TE, Toltzis P, Chu J, et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001-2003. Pediatr Infect Dis J 2006; 25:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hultén KG, Kaplan SL, Gonzalez BE, et al. Three-year surveillance of community onset health care-associated staphylococcus aureus infections in children. Pediatr Infect Dis J 2006; 25:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frank AL, Marcinak JF, Mangat PD, et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002; 21:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37:1257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanakunakorn C. Clindamycin therapy of Staphylococcus aureus endocarditis. Clinical relapse and development of resistance to clindamycin, lincomycin and erythromycin. Am J Med 1976; 60:419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naimi TS, LeDell KH, Boxrud DJ, et al. Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998. Clin Infect Dis 2001; 33:990.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sattler CA, Mason EO Jr, Kaplan SL. Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children. Pediatr Infect Dis J 2002; 21:910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fergie JE, Purcell K. Community-acquired methicillin-resistant Staphylococcus aureus infections in south Texas children. Pediatr Infect Dis J 2001; 20:860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frank AL, Marcinak JF, Mangat PD, Schreckenberger PC. Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children. Pediatr Infect Dis J 1999; 18:993.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006; 5:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almer LS, Shortridge VD, Nilius AM, et al. Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2002; 43:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weis S, Kesselmeier M, Davis JS, et al. Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect 2019; 25:818.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woods CR, Bradley JS, Chatterjee A, et al. Clinical Practice Guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 Guideline on Diagnosis and Management of Acute Hematogenous Osteomyelitis in Pediatrics. J Pediatric Infect Dis Soc 2021; 10:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karchmer AW. Staphylococcus aureus and vancomycin: the sequel. Ann Intern Med 1991; 115:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           González C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeil JC, Sommer LM, Boyle M, et al. Cefazolin Inoculum Effect and Methicillin-Susceptible Staphylococcus aureus Osteoarticular Infections in Children. Antimicrob Agents Chemother 2020; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Najia LM, Pyles E, Lopez-Ruiz A, Subedi B. Antistaphylococcal Efficacy of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients with Polymicrobial Infection with MSSA Bacteremia or Pneumonia. Adv Pharmacol Pharm Sci 2023; 2023:7684613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tunkel AR, Hasbun R, Bhimraj A, et al. 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis. Clin Infect Dis 2017.
          </a>
         </li>
         <li class="breakAll">
          Gorwitz RJ, Jernigan DB, Powers JH, et al. Strategies for clinical management of MRSA in the community: Summary of an experts' meeting convened by the Centers for Disease Control and Prevention. 2006. www.cdc.gov/ncidod/dhqp/pdf/ar/CAMRSA_ExpMtgStrategies.pdf (Accessed on September 13, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loeffler AM, Drew RH, Perfect JR, et al. Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients. Pediatr Infect Dis J 2002; 21:950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen CJ, Chiu CH, Lin TY, et al. Experience with linezolid therapy in children with osteoarticular infections. Pediatr Infect Dis J 2007; 26:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deville JG, Adler S, Azimi PH, et al. Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. Pediatr Infect Dis J 2003; 22:S158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan SL, Afghani B, Lopez P, et al. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2003; 22:S178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arrieta AC, Bradley JS, Popejoy MW, et al. Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia. Pediatr Infect Dis J 2018; 37:893.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bradley JS, Arrieta AC, Digtyar VA, et al. Daptomycin for Pediatric Gram-Positive Acute Hematogenous Osteomyelitis. Pediatr Infect Dis J 2020; 39:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsu AJ, Hamdy RF, Huang Y, et al. Association Between Vancomycin Trough Concentrations and Duration of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children. J Pediatric Infect Dis Soc 2018; 7:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDaniel LM, Fiawoo S, Tamma PD, Same RG. Trimethoprim-Sulfamethoxazole for Pediatric Osteoarticular Infections. J Pediatric Infect Dis Soc 2023; 12:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Messina AF, Namtu K, Guild M, et al. Trimethoprim-sulfamethoxazole therapy for children with acute osteomyelitis. Pediatr Infect Dis J 2011; 30:1019.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection. Ann Intern Med 1992; 117:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paul M, Bishara J, Yahav D, et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ 2015; 350:h2219.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben Mansour EH, Jacob E, Monchi M, et al. Occurrence of MRSA endocarditis during linezolid treatment. Eur J Clin Microbiol Infect Dis 2003; 22:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corne P, Marchandin H, Macia JC, Jonquet O. Treatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolid. Scand J Infect Dis 2005; 37:946.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruiz ME, Guerrero IC, Tuazon CU. Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid. Clin Infect Dis 2002; 35:1018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-Aguilar G, Hammerman WA, Mason EO Jr, Kaplan SL. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J 2003; 22:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martínez-Aguilar G, Avalos-Mishaan A, Hulten K, et al. Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2004; 23:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis 2004; 38:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191:2149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuchs PC, Barry AL, Brown SD. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother 2002; 49:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ardura MI, Mejías A, Katz KS, et al. Daptomycin therapy for invasive Gram-positive bacterial infections in children. Pediatr Infect Dis J 2007; 26:1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 2015; 132:1435.
          </a>
         </li>
         <li class="breakAll">
          Clinical and Laboratory Standards Institute (CLSI)/National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing; sixteenth informational supplement. NCCLS document M100-S16. National Committee for Clinical Laboratory Standards, Wayne, PA 2006.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44:1208.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mason EO, Lamberth LB, Hammerman WA, et al. Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005. J Clin Microbiol 2009; 47:1628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espedido BA, Jensen SO, van Hal SJ. Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia. J Antimicrob Chemother 2015; 70:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drew RH, Perfect JR, Srinath L, et al. Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group. J Antimicrob Chemother 2000; 46:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moise PA, Forrest A, Birmingham MC, Schentag JJ. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002; 50:1017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cha R, Brown WJ, Rybak MJ. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2003; 47:3960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis 2008; 46:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saravolatz LD, Pawlak J, Johnson LB. In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates. Clin Infect Dis 2012; 55:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Regen RB, Schuman SS, Chhim RF, et al. Vancomycin Treatment Failure in Children With Methicillin-Resistant Staphylococcus aureus Bacteremia. J Pediatr Pharmacol Ther 2019; 24:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2009; 29:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeil JC, Kok EY, Forbes AR, et al. Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome. Pediatr Infect Dis J 2016; 35:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hahn A, Frenck RW Jr, Allen-Staat M, et al. Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia. Ther Drug Monit 2015; 37:619.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McNeil JC, Kaplan SL, Vallejo JG. The Influence of the Route of Antibiotic Administration, Methicillin-Susceptibility, Vancomycin Duration and Serum Trough Concentration on Outcomes of Pediatric Staphylococcus aureus Bacteremic Osteoarticular Infection. Pediatr Infect Dis J 2016.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiorito TM, Luther MK, Dennehy PH, et al. Nephrotoxicity With Vancomycin in the Pediatric Population: A Systematic Review and Meta-Analysis. Pediatr Infect Dis J 2018; 37:654.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fortunov RM, Hulten KG, Hammerman WA, et al. Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates. Pediatrics 2007; 120:937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence. Clin Infect Dis 2007; 44:1543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamer C, de Beco V, Soler P, et al. Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients. Antimicrob Agents Chemother 1993; 37:281.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tan TQ, Mason EO Jr, Ou CN, Kaplan SL. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother 1993; 37:2401.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6057 Version 52.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15876948" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Treatment of community-associated methicillin-resistant Staphylococcus aureus infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19935448" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19935448" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36165630" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Reduced Ceftaroline Susceptibility among Invasive MRSA Infections in Children: a Clinical and Genomic Investigation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18162942" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The treatment of community-acquired methicillin-resistant Staphylococcus aureus infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16983604" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Infective pyomyositis and myositis in children in the era of community-acquired, methicillin-resistant Staphylococcus aureus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19489710" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31033905" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical Characteristics and Outcomes of Staphylococcus aureus Implant-associated Infections in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20445480" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Infection after spinal fusion for pediatric spinal deformity: thirty years of experience at a single institution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29088025" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Postoperative Spinal Implant Infections in Children: Risk Factors, Characteristics and Outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27927517" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Management of Spinal Implants in Acute Pediatric Surgical Site Infections: A Multicenter Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27927517" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Management of Spinal Implants in Acute Pediatric Surgical Site Infections: A Multicenter Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32839650" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Vancomycin Therapeutic Drug Monitoring in Children: New Recommendations, Similar Challenges.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32191793" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29893805" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Vancomycin Monotherapy May Be Insufficient to Treat Methicillin-resistant Staphylococcus aureus Coinfection in Children With Influenza-related Critical Illness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29893812" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The Concern for Vancomycin Failure in the Treatment of Pediatric Staphylococcus aureus Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27078119" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : A Multicenter, Randomized, Observer-blinded, Active-controlled Study Evaluating the Safety and Effectiveness of Ceftaroline Compared With Ceftriaxone Plus Vancomycin in Pediatric Patients With Complicated Community-acquired Bacterial Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12015695" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12913766" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16102659" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Implications of methicillin-resistant Staphylococcus aureus as a community-acquired pathogen in pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28403050" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Ceftaroline Activity Tested Against Bacterial Isolates Causing Community-acquired Respiratory Tract Infections and Skin and Skin Structure Infections in Pediatric Patients From United States Hospitals: 2012-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27164462" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A Multicenter, Randomized, Observer-blinded, Active-controlled Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27093162" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16567987" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Clinical and molecular epidemiology of community-acquired methicillin-resistant Staphylococcus aureus infections among children with risk factors for health care-associated infection: 2001-2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16567988" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Three-year surveillance of community onset health care-associated staphylococcus aureus infections in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12182377" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14557972" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1045861" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Clindamycin therapy of Staphylococcus aureus endocarditis. Clinical relapse and development of resistance to clindamycin, lincomycin and erythromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11528570" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Epidemiology and clonality of community-acquired methicillin-resistant Staphylococcus aureus in Minnesota, 1996-1998.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12394811" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Prospective comparison of risk factors and demographic and clinical characteristics of community-acquired, methicillin-resistant versus methicillin-susceptible Staphylococcus aureus infection in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11734764" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Community-acquired methicillin-resistant Staphylococcus aureus infections in south Texas children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10571437" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Community-acquired and clindamycin-susceptible methicillin-resistant Staphylococcus aureus in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16469106" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11294701" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : The changing epidemiology of Staphylococcus aureus?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12106956" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30928559" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Cefazolin versus anti-staphylococcal penicillins for the treatment of patients with Staphylococcus aureus bacteraemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34350458" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clinical Practice Guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 Guideline on Diagnosis and Management of Acute Hematogenous Osteomyelitis in Pediatrics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1929043" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Staphylococcus aureus and vancomycin: the sequel.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9709046" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Staphylococcus aureus infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10524959" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32660989" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Cefazolin Inoculum Effect and Methicillin-Susceptible Staphylococcus aureus Osteoarticular Infections in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38075388" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Antistaphylococcal Efficacy of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients with Polymicrobial Infection with MSSA Bacteremia or Pneumonia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28203777" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28203777" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : 2017 Infectious Diseases Society of America's Clinical Practice Guidelines for Healthcare-Associated Ventriculitis and Meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12394819" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17984803" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Experience with linezolid therapy in children with osteoarticular infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14520141" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14520144" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29406465" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Randomized Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care in Pediatric Patients With Staphylococcal Bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32639465" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Daptomycin for Pediatric Gram-Positive Acute Hematogenous Osteomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28992126" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Association Between Vancomycin Trough Concentrations and Duration of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37757866" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Trimethoprim-Sulfamethoxazole for Pediatric Osteoarticular Infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21817950" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Trimethoprim-sulfamethoxazole therapy for children with acute osteomyelitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1503330" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Trimethoprim-sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25977146" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12768433" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Occurrence of MRSA endocarditis during linezolid treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16308242" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Treatment failure of methicillin-resistant Staphylococcus aureus endocarditis with linezolid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12355391" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Endocarditis caused by methicillin-resistant Staphylococcus aureus: treatment failure with linezolid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12867833" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15295218" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15034832" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15898002" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11864946" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : In vitro bactericidal activity of daptomycin against staphylococci.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18043450" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Daptomycin therapy for invasive Gram-positive bacterial infections in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26373316" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26373316" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17407040" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19403769" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Vancomycin MICs for Staphylococcus aureus vary by detection method and have subtly increased in a pediatric population since 2005.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25406295" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Ceftaroline fosamil salvage therapy: an option for reduced-vancomycin-susceptible MRSA bacteraemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11062197" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Treatment of methicillin-resistant staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. For the Synercid Emergency-Use Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12461026" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14638509" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18257700" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22615331" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31337994" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Vancomycin Treatment Failure in Children With Methicillin-Resistant Staphylococcus aureus Bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19873687" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26646549" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26378371" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Evaluation of Target Attainment of Vancomycin Area Under the Curve in Children With Methicillin-Resistant Staphylococcus Aureus Bacteremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28027279" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : The Influence of the Route of Antibiotic Administration, Methicillin-Susceptibility, Vancomycin Duration and Serum Trough Concentration on Outcomes of Pediatric Staphylococcus aureus Bacteremic Osteoarticular Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29280786" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Nephrotoxicity With Vancomycin in the Pediatric Population: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17974729" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Evaluation and treatment of community-acquired Staphylococcus aureus infections in term and late-preterm previously healthy neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17516396" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Counterpoint: Vancomycin and Staphylococcus aureus--an antibiotic enters obsolescence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8452359" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15509186" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8285624" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
